G1 Therapeutics Inc (GTHX)
7.15
0.00 (0.00%)
USD |
NASDAQ |
Sep 18, 16:00
G1 Therapeutics Profit Margin (Quarterly): -33.05% for June 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -33.05% |
| March 31, 2024 | -70.59% |
| December 31, 2023 | -73.14% |
| September 30, 2023 | -148.0% |
| June 30, 2023 | 20.55% |
| March 31, 2023 | -213.2% |
| December 31, 2022 | -328.3% |
| September 30, 2022 | -107.2% |
| June 30, 2022 | -373.1% |
| Date | Value |
|---|---|
| March 31, 2022 | -712.7% |
| December 31, 2021 | -690.5% |
| September 30, 2021 | -874.2% |
| June 30, 2021 | -596.9% |
| March 31, 2021 | -186.0% |
| December 31, 2020 | -153.2% |
| September 30, 2020 | -43.89% |
| June 30, 2020 | -1.46K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-1.46K%
Minimum
Jun 2020
20.55%
Maximum
Jun 2023
-355.4%
Average
-186.0%
Median
Mar 2021
Profit Margin (Quarterly) Benchmarks
| PetIQ Inc | 4.66% |
| Biomarin Pharmaceutical Inc | 14.22% |
| Regeneron Pharmaceuticals Inc | 36.03% |
| Verrica Pharmaceuticals Inc | -- |
| Terns Pharmaceuticals Inc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -118.9% |
| Return on Assets | -37.11% |
| Return on Invested Capital | -52.13% |
| Gross Profit Margin (Quarterly) | 95.57% |
| Operating Margin (Quarterly) | -21.36% |
| Return on Net Operating Assets | -140.4% |